Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine

Psychopharmacology

Volumn 213, Issue 1, 2011, Pages 1-9

  Yamashita, Hakuei ^a,b   Yoda, Hiroo ^a,b   Kuroki, Noriomi ^b,c   Kuwabara, Michiko ^a   Odagaki, Yuji ^b   Kazawa, Tetsushi ^b   Toyoshima, Ryoichi ^b   Maruki, Taeko ^a  

^a Moro Hospital   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Angiotensin II type 1 receptor blocker; Insulin resistance; Olanzapine

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; OLANZAPINE; TELMISARTAN; VALSARTAN;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOREACTIVITY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIPSYCHOTIC AGENTS; BENZIMIDAZOLES; BENZOATES; BENZODIAZEPINES; FEMALE; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; MALE; MIDDLE AGED; RECEPTOR, ANGIOTENSIN, TYPE 1; SCHIZOPHRENIA; TETRAZOLES; VALINE;

EID: 78651254559     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-2002-9     Document Type: Article

References (49)

1. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders (DSM-IV), 4th edn. American Psychiatric Association Publications Division, Washington DC
2. RA Benndorf T Rudolph D Appel E Schwedhelm R Maas F Schulze E Silberhorn RH Böger 2006 Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension Metabolism 55 1159 1164 1:CAS:528:DC%2BD28XotlCisbk%3D 10.1016/j.metabol.2006.04.013 16919533 (Pubitemid 44219053)
3. JT Callaghan RF Bergstrom LR Ptak CM Beasley 1999 Olanzapine. Pharmacokinetic and pharmacodynamic profile Clin Pharmacokinet 37 177 193 1:CAS:528:DyaK1MXmsFKrsL8%3D 10.2165/00003088-199937030-00001 10511917 (Pubitemid 29452754)
4. CU Correll AM Frederickson JM Kane P Manu 2006 Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs J Clin Psychiatry 67 575 583 1:CAS:528:DC%2BD28XlsVegsbY%3D 10.4088/JCP.v67n0408 16669722
5. Y Cui RS Blumenthal JA Flaws MK Whiteman P Langenberg PS Bachorik TL Bush 2001 Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality Arch Intern Med 161 1413 1419 1:STN:280:DC%2BD3MvjsFygtA%3D%3D 10.1001/archinte.161.11.1413 11386890
6. M De Hert D Van Eyck L Hanssens H Peuskens E Thys M Wampers A Scheen J Peuskens 2006 Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? Eur Psychiatry 21 224 226 10.1016/j.eurpsy.2005.05.011 16139484 (Pubitemid 43929243)
7. T Ebner G Heinzel A Prox K Beschke H Wachsmuth 1999 Disposition and chemical stability of telmisartan 1-O-acylglucuronide Drug Metab Dispos 27 1143 1149 1:CAS:528:DyaK1MXmtlalur0%3D 10497140
8. Eli Lilly Japan KK (2010) Zyprexa® package insert, 14th edn. revised March, 2010 (in Japanese)
9. R Fogari G Derosa A Zoppi A Rinaldi P Lazzari E Fogari A Mugellini P Preti 2005 Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients Hypertens Res 28 209 214 1:CAS:528:DC%2BD2MXltlCqsrg%3D 10.1291/hypres.28.209 16097363 (Pubitemid 40812604)
10. M Fukushima H Suzuki Y Seino 2004 Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes Diabetes Res Clin Pract 66 Suppl 1 S37 S43 1:CAS:528:DC%2BD2cXhtVantrfE 10.1016/j.diabres.2003.11. 024 15563978 (Pubitemid 39572582)
11. JM Haro D Suarez D Novick J Brown J Usall D Naber SOHO Study Group 2007 Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results Eur Neuropsychopharmacol 17 235 244 1:CAS:528:DC%2BD2sXpvVygtg%3D%3D 10.1016/j.euroneuro.2006.09.005 17137759 (Pubitemid 46164772)
12. DC Henderson E Cagliero PM Copeland CP Borba E Evins D Hayden MT Weber EJ Anderson DB Allison TB Daley D Schoenfeld DC Goff 2005 Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis Arch Gen Psychiatry 62 19 28 1:CAS:528:DC%2BD2MXht1Kns7o%3D 10.1001/archpsyc.62.1.19 15630069 (Pubitemid 40096067)
13. Japan Diabetes Society (2007) Treatment guide for diabetes 2007. Bunkodo Co., Ltd. Tokyo, Japan
14. S Julius SE Kjeldsen M Weber HR Brunner S Ekman L Hansson T Hua J Laragh GT McInnes L Mitchell F Plat A Schork B Smith A Zanchetti VALUE trial group 2004 Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2022 2031 1:CAS:528:DC%2BD2cXltVCitro%3D 10.1016/S0140-6736(04)16451-9 15207952 (Pubitemid 38781102)
15. Kay SR, Opler LA, Fizbein A (1986) The positive and negative syndrome scale (PANSS) manual. Multi-Health System, North Tonawanda
16. BJ Kinon BR Basson JA Gilmore GD Tollefson 2001 Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia J Clin Psychiatry 62 92 100 1:CAS:528:DC%2BD3MXit1eltro%3D 10.4088/JCP.v62n0204 11247108
17. EA Koller PM Doraiswamy 2002 Olanzapine-associated diabetes mellitus Pharmacotherapy 22 841 852 1:CAS:528:DC%2BD38XlslCltrk%3D 10.1592/phco.22.11. 841.33629 12126218
18. SM Kyvelou GP Vyssoulis EA Karpanou DN Adamopoulos AI Zervoudaki PG Pietri CI Stefanadis 2006 Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial Hellenic J Cardiol 47 21 28 16532712
19. M Laakso 1993 How good a marker is insulin level for insulin resistance? Am J Epidemiol 137 959 965 1:STN:280:DyaK3szgsVeksQ%3D%3D 8317453
20. S Leucht C Corves D Arbter RR Engel C Li JM Davis 2009 Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet 373 31 41 1:CAS:528:DC%2BD1MXht1Wqsw%3D%3D 10.1016/S0140-6736(08)61764-X 19058842
21. JA Lieberman TS Stroup JP McEvoy MS Swartz RA Rosenheck DO Perkins RS Keefe SM Davis CE Davis BD Lebowitz J Severe JK Hsiao Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators 2005 Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 1209 1223 1:CAS:528:DC%2BD2MXhtVeltL%2FN 10.1056/NEJMoa051688 16172203 (Pubitemid 41345943)
22. AD Liese EJ Mayer-Davis SM Haffner 1998 Development of the multiple metabolic syndrome: an epidemiologic perspective Epidemiol Rev 20 157 172 1:STN:280:DyaK1M7hvVSrsg%3D%3D 9919436
23. L Maayan J Vakhrusheva CU Correll 2010 Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis Neuropsychopharmacology 35 1520 1530 1:CAS:528:DC%2BC3cXmtVSnt78%3D 10.1038/npp.2010.21 20336059
24. H Makino M Haneda T Babazono T Moriya S Ito Y Iwamoto R Kawamori M Takeuchi S Katayama INNOVATION Study Group 2008 Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study Hypertens Res 31 657 664 1:CAS:528:DC%2BD1cXos12jurY%3D 10.1291/hypres.31.657 18633177 (Pubitemid 351772856)
25. G Mancia G De Backer A Dominiczak R Cifkova R Fagard G Germano G Grassi AM Heagerty SE Kjeldsen S Laurent K Narkiewicz L Ruilope A Rynkiewicz RE Schmieder HA Boudier A Zanchetti A Vahanian J Camm R De Caterina V Dean K Dickstein G Filippatos C Funck-Brentano I Hellemans SD Kristensen K McGregor U Sechtem S Silber M Tendera P Widimsky JL Zamorano S Erdine W Kiowski E Agabiti-Rosei E Ambrosioni LH Lindholm M Viigimaa S Adamopoulos E Agabiti-Rosei E Ambrosioni V Bertomeu D Clement S Erdine C Farsang D Gaita G Lip JM Mallion AJ Manolis PM Nilsson E O'Brien P Ponikowski J Redon F Ruschitzka J Tamargo P van Zwieten B Waeber B Williams Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC) J Hypertens 25 1105 1187 1:CAS:528:DC%2BD2sXmtlWnsr0%3D 10.1097/HJH.0b013e3281fc975a 17563527 (Pubitemid 46924065)
26. M Matsuda RA DeFronzo 1999 Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp Diab Care 22 1462 1470 1:STN:280:DyaK1MvgvVertQ%3D%3D 10.2337/diacare.22.9.1462 (Pubitemid 29418240)
27. DR Matthews JP Hosker AS Rudenski BA Naylor DF Treacher RC Turner 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 412 419 1:CAS:528:DyaL2MXlslKnu7k%3D 10.1007/BF00280883 3899825 (Pubitemid 15018832)
28. KI Melkersson ML Dahl 2003 Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses Psychopharmacology (Berl) 170 157 166 1:CAS:528:DC%2BD3sXosFWrs7w%3D 10.1007/s00213-003-1529-4 (Pubitemid 37421527)
29. S Mochizuki B Dahlöf M Shimizu K Ikewaki M Yoshikawa I Taniguchi M Ohta T Yamada K Ogawa K Kanae M Kawai S Seki F Okazaki M Taniguchi S Yoshida N Tajima Jikei Heart Study group 2007 Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study Lancet 28 1431 1439 10.1016/S0140-6736(07)60669-2 (Pubitemid 46635780)
30. P Müller G Flesch M de Gasparo M Gasparini H Howald 1997 Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects Eur J Clin Pharmacol 52 441 449 10.1007/s002280050317 9342579 (Pubitemid 27395643)
31. JM Nagel AB Tietz B Göke KG Parhofer 2006 The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects Metabolism 55 1149 1154 1:CAS:528:DC%2BD28XotlCisbs%3D 10.1016/j.metabol.2006. 04.011 16919531 (Pubitemid 44215933)
32. A Nakashima H Kawashita N Masuda C Saxer M Niina Y Nagae K Iwasaki 2005 Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes Xenobiotica 35 589 602 1:CAS:528:DC%2BD2MXhtVWitLfO 10.1080/00498250500158175 16192110 (Pubitemid 41242916)
33. HA Nasrallah 2006 Metabolic findings from the CATIE trial and their relation to tolerability CNS Spectr 11 Suppl 7 32 39 16816798
34. NAVIGATOR Study Group JJ McMurray RR Holman SM Haffner MA Bethel B Holzhauer TA Hua Y Belenkov M Boolell JB Buse BM Buckley AR Chacra FT Chiang B Charbonnel CC Chow MJ Davies P Deedwania P Diem D Einhorn V Fonseca GR Fulcher Z Gaciong S Gaztambide T Giles E Horton H Ilkova T Jenssen SE Kahn H Krum M Laakso LA Leiter NS Levitt V Mareev F Martinez C Masson T Mazzone E Meaney R Nesto C Pan R Prager SA Raptis GE Rutten H Sandstroem F Schaper A Scheen O Schmitz I Sinay V Soska S Stender G Tamás G Tognoni J Tuomilehto AS Villamil J Vozár RM Califf 2010 Effect of valsartan on the incidence of diabetes and cardiovascular events N Engl J Med 362 1477 1490 1:CAS:528:DC%2BC3cXlt12rsbo%3D 10.1056/NEJMcp0909392 20228403
35. JW Newcomer DW Haupt R Fucetola AK Melson JA Schweiger BP Cooper G Selke 2002 Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia Arch Gen Psychiatry 59 337 345 1:CAS:528:DC%2BD38Xjt1Wqsbo%3D 10.1001/archpsyc.59.4.337 11926934
36. T Ogihara K Kikuchi H Matsuoka T Fujita J Higaki M Horiuchi Y Imai T Imaizumi S Ito H Iwao K Kario Y Kawano S Kim-Mitsuyama G Kimura H Matsubara H Matsuura M Naruse I Saito K Shimada K Shimamoto H Suzuki S Takishita N Tanahashi T Tsuchihashi M Uchiyama S Ueda H Ueshima S Umemura T Ishimitsu H Rakugi Japanese Society of Hypertension Committee 2009 The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009) Hypertens Res 32 3 107 1:CAS:528:DC%2BD1MXltVOjtLY%3D 19300436
37. GM Reaven 1988 Banting lecture 1988. Role of insulin resistance in human disease Diabetes 37 1595 1607 1:STN:280:DyaL1M%2Flt12msQ%3D%3D 10.2337/diabetes.37.12.1595 3056758
38. T Rönnemaa M Laakso K Pyörälä V Kallio P Puukka 1991 High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic subjects Arterioscler Thromb 11 80 90 1988007
39. MC Ryan P Collins JH Thakore 2003 Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia Am J Psychiatry 160 284 289 10.1176/appi.ajp.160.2.284 12562574 (Pubitemid 41110453)
40. M Schupp J Janke R Clasen T Unger U Kintscher 2004 Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity Circulation 109 2054 2057 1:CAS:528:DC%2BD2cXjsVWqsrs%3D 10.1161/01.CIR.0000127955.36250.65 15117841 (Pubitemid 38620211)
41. T Shiuchi M Iwai HS Li L Wu LJ Min JM Li M Okumura TX Cui M Horiuchi 2004 Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice Hypertension 43 1003 1010 1:CAS:528:DC%2BD2cXjt1Gmsbc%3D 10.1161/01.HYP.0000125142.41703.64 15037562 (Pubitemid 38579905)
42. K Shiwaku E Anuurad B Enkhmaa A Nogi K Kitajima M Yamasaki T Yoneyama T Oyunsuren Y Yamane 2005 Predictive values of anthropometric measurements for multiple metabolic disorders in Asian populations Diabetes Res Clin Pract 69 52 62 10.1016/j.diabres.2004.11.001 15955387 (Pubitemid 40813412)
43. J Stangier CA Su W Roth 2000 Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients J Int Med Res 28 149 167 1:CAS:528:DC%2BD3cXmsFaksL4%3D 11014323
44. AG Tabák M Jokela TN Akbaraly EJ Brunner M Kivimäki DR Witte 2009 Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study Lancet 373 2215 2221 10.1016/S0140-6736(09)60619-X 19515410
45. C Top BY Cingözbay H Terekeci Y Küçükardali ME Onde M Danaci 2002 The effects of valsartan on insulin sensitivity in patients with primary hypertension J Int Med Res 30 15 20 1:CAS:528:DC%2BD38XislChs7Y%3D 11921494 (Pubitemid 34618717)
46. G Viberti NM Wheeldon MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators 2002 Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect Circulation 106 672 678 1:CAS:528:DC%2BD38XmvFSmsL8%3D 10.1161/01.CIR.0000024416.33113.0A 12163426 (Pubitemid 34851925)
47. M Vogeser D König I Frey HG Predel KG Parhofer A Berg 2007 Fasting serum insulin and the homeostasis model of insulin resistance (HOMA-IR) in the monitoring of lifestyle interventions in obese persons Clin Biochem 40 964 968 1:CAS:528:DC%2BD2sXpsFGrtL0%3D 10.1016/j.clinbiochem.2007.05.009 17583689 (Pubitemid 47301794)
48. H Yamashita H Yoda T Maruki R Toyoshima 2008 Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: a case report Prog Neuropsychopharmacol Biol Psychiatry 32 308 310 1:CAS:528:DC%2BD1cXptlaisA%3D%3D 10.1016/j.pnpbp.2007.08. 022 17884270
49. T Yamauchi J Kamon H Waki K Murakami K Motojima K Komeda T Ide N Kubota Y Terauchi K Tobe H Miki A Tsuchida Y Akanuma R Nagai S Kimura T Kadowaki 2001 The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance J Biol Chem 276 41245 41254 1:CAS:528:DC%2BD3MXosVKgtrg%3D 10.1074/jbc.M103241200 11533050